30 results on '"Farkowski M"'
Search Results
2. The effect of amiodarone given periprocedurally on the effectiveness of catheter ablation in patients with persistent atrial fibrillation refractory to cardioversion
- Author
-
Ehrenhalt, G, primary, Ciszewski, J, additional, Farkowski, M, additional, Baranowski, R, additional, Rymuza, H, additional, Jedrzejczyk, B, additional, Jankowska, A, additional, Kowalik, I, additional, Maciag, A, additional, Syska, P, additional, Lewandowski, M, additional, Kolakowski, K, additional, Zalewska, J, additional, and Pytkowski, M, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Prevention of venous thromboembolism after right heart-sided electrophysiological procedures: results of an EHRA survey
- Author
-
Mugnai, G, primary, Farkowski, M, additional, Tomasi, L, additional, Roten, L, additional, Migliore, F, additional, De Asmundis, C, additional, Conte, G, additional, Boveda, S, additional, and Chun, J K R, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Efficacy and safety of antiarrhythmic drugs for pharmacological cardioversion of atrial fibrillation depending on gender: a subanalysis of CANT II Study
- Author
-
Wybraniec, M, primary, Maciag, A, additional, Miskowiec, D, additional, Balsam, P, additional, Wojcik, M, additional, Wrobel, W, additional, Farkowski, M, additional, Cwiek-Rebowska, E, additional, Szolkiewicz, M, additional, Bula, K, additional, Krzowski, B, additional, Kozinski, M, additional, Kasprzak, J, additional, Szwed, H, additional, and Mizia-Stec, K, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Computed tomography with positron emission tomography is more useful in local than systemic infectious process related to cardiac implanted electrotherapy device: a prospective controlled multicenter diagnostic intervention PET-Guidance Trial
- Author
-
Marciniak-Emmons, M. B., Świerżyńska, E., Mazurek, A., Syska, P., Farkowski, M. M., Firek, B., Juszczyk, U., Zakrzewska-Koperska, J., Zając, D., Oręziak, A., Maciąg, A., Kowalik, I., Pytkowski, M., Szwed, H., Bilińska, M., Szumowski, Ł., Dziuk, M., and Sterliński, M.
- Abstract
Assess the diagnostic value of 18-F FDG PET/CT in cardiac implantable electronic devices (CIED) infections in facilitating diagnostic process and optimizing decision-making process.Study group (n = 21) patients with initial suspected diagnosis of CIED-related infection or fever of unknown origin and patients referred for device removal due to infection. Control group (n = 13) patients with implanted CIED, who underwent PET/CT due to other non-infectious indications and had no data for infectious process in follow-up.PET/CT scan showed pocket infection in 12 patients (including 1 in whom infection was not finally diagnosed—the examination was performed early after the implantation procedure—1.5 months), increased tracer uptake in intravascular lead part in 3 patients, and increased uptake in intracardiac part in 5 patients.We found that sensitivity, specificity, positive predictive value, and negative predictive value of the diagnosis made by PET/CT in generator pocket infection was 91.7%, 70%, 78.6%, 87.5% and in lead-dependent intracardiac infection 100%, 47.1%, 35.7%, 100% respectively. PET/CT scan enabled reclassification of diagnosis from possible to definite CIED-related infection in 6 out of 9 patients, and to excluded in 3 out of 9.Establishing diagnosis of device related infections may be challenging due to non-specific symptoms. Incorporation of PET/CT scan in the diagnostic schema can improve accuracy and timing of the diagnosis and help to assess the extent of infection. PET/CT is more useful in local than systemic infectious process related to cardiac implanted electrotherapy device.
- Published
- 2024
- Full Text
- View/download PDF
6. Regularnie niemiarowy częstoskurcz z wąskimi zespołami QRS: co to za arytmia?
- Author
-
Supryn, Rafał, Farkowski, M., and Gil, R.
- Published
- 2024
7. Effectiveness and safety of bipolar ablation of heart arrhythmia. A systematic review with meta-analysis
- Author
-
Farkowski, M, primary, Truszkowska, N, additional, Zielinska, A, additional, Karlinski, M, additional, Futyma, P, additional, Pytkowski, M, additional, Hryniewiecki, T, additional, and Maciag, A, additional
- Published
- 2022
- Full Text
- View/download PDF
8. Dostęp naczyniowy w krioablacji AF u pacjenta po leczeniu raka prostaty.
- Author
-
Jędrychowski, Tomasz, Ziaja, P., Wesołek, E., and Farkowski, M.
- Published
- 2024
9. Uporczywy kaszel po ablacji kriobalonowej jako początkowy objaw zakażenia dróg oddechowych Bordetella pertussis.
- Author
-
Jodkowska, Irena, Trębińska, P., Gortych, R., and Farkowski, M.
- Published
- 2024
10. Pharmacological cardioversion of recent-onset atrial fibrillation in patients with chronic kidney disease: sub-analysis of the CANT study
- Author
-
Ceynowa-Sielawko, B, primary, Wybraniec, M, additional, Topp-Zielinska, A, additional, Maciag, A, additional, Miskowiec, D, additional, Krzowski, B, additional, Balsam, P, additional, Wojcik, M, additional, Wrobel, W, additional, Farkowski, M, additional, Kozinski, M, additional, Kasprzak, J, additional, Szwed, H, additional, Mizia-Stec, K, additional, and Szolkiewicz, M, additional
- Published
- 2021
- Full Text
- View/download PDF
11. Prospective evaluation of an algorithm for arrhythmogenic foci localization in right ventricular outflow tract
- Author
-
Pytkowski, M., Maciag, A., Farkowski, M., Jankowska, A., Kowalik, I., Kraska, A., and Szwed, H.
- Published
- 2011
12. Antazoline for pharmacological cardioversion of atrial fibrillation: the results of the high-volume multicenter CANT study
- Author
-
Wybraniec, M, primary, Maciag, A, additional, Miskowiec, D, additional, Ceynowa-Sielawko, B, additional, Balsam, P, additional, Wrobel, W, additional, Farkowski, M, additional, Cwiek-Rebowska, E, additional, Szolkiewicz, M, additional, Ozieranski, K, additional, Krzowski, B, additional, Kozinski, M, additional, Kasprzak, J, additional, Szwed, H, additional, and Mizia-Stec, K, additional
- Published
- 2020
- Full Text
- View/download PDF
13. Gender-related differences in outcomes and resource utilization in patients undergoing radiofrequency ablation of supraventricular tachycardia: results from Patients' Perspective on Radiofrequency Catheter Ablation of AVRT and AVNRT Study
- Author
-
Farkowski, M. M., primary, Pytkowski, M., additional, Maciag, A., additional, Golicki, D., additional, Wood, K. A., additional, Kowalik, I., additional, Kuteszko, R., additional, and Szwed, H., additional
- Published
- 2014
- Full Text
- View/download PDF
14. Utility of automated matching technique for interpretation of pace mapping in patients ablated due to outflow tract ventricular arrhythmias
- Author
-
Kuteszko, R., primary, Pytkowski, M., additional, Farkowski, M. M., additional, Maciag, A., additional, Jankowska, A., additional, Zajac, D., additional, Kowalik, I., additional, and Szwed, H., additional
- Published
- 2013
- Full Text
- View/download PDF
15. Poster Session 1
- Author
-
Deshmukh, A., primary, Sharma, S. S., additional, Gobal, F. G., additional, Singla, S. S., additional, Hebbar, P. H., additional, Paydak, H. P., additional, Igarashi, M., additional, Tada, H., additional, Sekiguchi, Y., additional, Yamasaki, H., additional, Kuroki, K., additional, Machino, T., additional, Yoshida, K., additional, Aonuma, K., additional, Shavadia, J., additional, Otieno, H., additional, Yonga, G., additional, Jinah, A., additional, Qvist, J. F., additional, Soerensen, P. H., additional, Dixen, U., additional, Ramirez-Marrero, M. A., additional, Perez-Villardon, B., additional, Gaitan-Roman, D., additional, Jimenez-Navarro, M., additional, Delgado-Prieto, J. L., additional, De Teresa-Galvan, E., additional, De Mora-Martin, M., additional, Deshmukh, A., additional, Hebbar, P. B., additional, Wei, W. X., additional, Bardari, S., additional, Zecchin, M., additional, Salame', R., additional, Vitali Serdoz, L., additional, Di Lenarda, A., additional, Guerrini, N., additional, Barbati, G., additional, Sinagra, G., additional, Hanazawa, K., additional, Kaitani, K., additional, Nakagawa, Y., additional, Lenaerts, I., additional, Driesen, R., additional, Hermida, N., additional, Heidbuchel, H., additional, Janssens, S., additional, Balligand, J. L., additional, Sipido, K. R., additional, Willems, R., additional, Sehra, R., additional, Krummen, D., additional, Briggs, C., additional, Narayan, S., additional, Tanaka, Y., additional, Hirao, K., additional, Nakamura, T., additional, Inaba, O., additional, Yagishita, A., additional, Higuchi, K., additional, Hachiya, H., additional, Isobe, M., additional, Kallergis, E., additional, Kanoupakis, E. M., additional, Mavrakis, H. E., additional, Goudis, C. A., additional, Maliaraki, N. E., additional, Vardas, P. E., additional, Kiuchi, K., additional, Piorkowski, C., additional, Kircher, S., additional, Gaspar, T., additional, Watanabe, N., additional, Bollmann, A., additional, Hindricks, G., additional, Wauters, K., additional, Grosse, A., additional, Raffa, S., additional, Brunelli, M., additional, Geller, J. C., additional, Maggioni, A. P., additional, Gonzini, L., additional, Gussoni, G., additional, Vescovo, G., additional, Gulizia, M., additional, Pirelli, S., additional, Mathieu, G., additional, Di Pasquale, G., additional, Salame, R., additional, Magnani, S., additional, Sakamoto, T., additional, Kumagai, K., additional, Fuke, E., additional, Nishiuchi, S., additional, Hayashi, T., additional, Miki, Y., additional, Naito, S., additional, Oshima, S., additional, Hof, I. E., additional, Vonken, E., additional, Velthuis, B. K., additional, Meine, M., additional, Hauer, R. N. W., additional, Loh, K. P., additional, Na, J. O., additional, Choi, C. U., additional, Kim, E. J., additional, Rha, S. W., additional, Park, C. G., additional, Seo, H. S., additional, Oh, D. J., additional, Lim, H. E., additional, Wichterle, D., additional, Bulkova, V., additional, Fiala, M., additional, Chovancik, J., additional, Simek, J., additional, Peichl, P., additional, Cihak, R., additional, Kautzner, J., additional, Glick, A., additional, Viskin, S., additional, Belhassen, B., additional, Navarrete, A., additional, Conte, F., additional, Ishti, A., additional, Sai, D., additional, Moran, M., additional, Chitovova, Z., additional, Ahmed, H., additional, Mares, K., additional, Skoda, J., additional, Sediva, L., additional, Petru, J., additional, Reddy, V. Y., additional, Neuzil, P., additional, Schmidt, M., additional, Dorwarth, U., additional, Leber, A., additional, Wankerl, M., additional, Krieg, J., additional, Straube, F., additional, Reif, S., additional, Hoffmann, E., additional, Mikhaylov, E., additional, Tikhonenko, V., additional, Lebedev, D., additional, Shin, S. Y., additional, Yong, H. S., additional, Choi, J. I., additional, Kim, S. H., additional, Matsuo, S., additional, Yamane, T., additional, Hioki, M., additional, Ito, K., additional, Narui, R., additional, Date, T., additional, Sugimoto, K., additional, Yoshimura, M., additional, Rolf, S., additional, Sommer, P., additional, Batalov, R., additional, Popov, S., additional, Antonchenko, I., additional, Suslova, T., additional, Fichtner, S., additional, Czudnochowsky, U., additional, Estner, H. L., additional, Ammar, S., additional, Reents, T., additional, Jilek, C., additional, Hessling, G., additional, Deisenhofer, I., additional, Pokushalov, E., additional, Romanov, A., additional, Corbucci, G., additional, Artemenko, S., additional, Losik, D., additional, Shabanov, V., additional, Turov, A., additional, Elesin, D., additional, Abramov, M., additional, Sanders, P., additional, Jais, P., additional, Roberts-Thomson, K., additional, Fukumoto, K., additional, Takatsuki, S., additional, Kimura, T., additional, Nishiyama, N., additional, Aizawa, Y., additional, Sato, T., additional, Miyoshi, S., additional, Fukuda, K., additional, Roux, Y., additional, Tenkorang, J., additional, Carroz, P., additional, Schlaepfer, J., additional, Pascale, P., additional, Forclaz, A., additional, Fromer, M., additional, Pruvot, E., additional, Sknouril, L., additional, Nevralova, R., additional, Dorda, M., additional, Januska, J., additional, Santi, R., additional, Geller, C., additional, Nakamura, K., additional, Kasseno, K., additional, Taniguchi, K., additional, Wutzler, A., additional, Huemer, M., additional, Parwani, A., additional, Boldt, L. H., additional, Blaschke, D., additional, Dietz, R., additional, Haverkamp, W., additional, Coutu, B., additional, Malanuk, R., additional, Ait Said, M., additional, Vicentini, A., additional, Schade, S., additional, Ando, K., additional, Rousseauplasse, A., additional, Deering, T., additional, Picarra, B. C., additional, Santos, A. R., additional, Dionisio, P., additional, Semedo, P., additional, Matos, R., additional, Leitao, M., additional, Jacinto, A., additional, Trinca, M., additional, Wan, C., additional, Glad, J., additional, Szymkiewicz, S., additional, Habibovic, M., additional, Versteeg, H., additional, Pelle, A. J. M., additional, Theuns, D. A. M. J., additional, Jordaens, L., additional, Pedersen, S. S., additional, Pakarinen, S., additional, Toivonen, L., additional, Taggeselle, J., additional, Frey, A., additional, Birkenhagen, A., additional, Kohler, S., additional, Maier, S. K. G., additional, Lobitz, N., additional, Paule, S., additional, Becher, J., additional, Mustafa, G., additional, Ibrahim, A., additional, King, G., additional, Foley, B., additional, Wilkoff, B., additional, Freedman, R., additional, Hayes, D., additional, Kalbfleisch, S., additional, Kutalek, S., additional, Schaerf, R., additional, Fazal, I. A., additional, Tynan, M., additional, Plummer, C. J., additional, Mccomb, J. M., additional, Oto, A., additional, Aytemir, K., additional, Yorgun, H., additional, Canpolat, U., additional, Kaya, E. B., additional, Tokgozoglu, L., additional, Kabakci, G., additional, Ozkutlu, H., additional, Greenberg, S., additional, Hamati, F., additional, Styperek, R., additional, Alonso, J., additional, Peress, D., additional, Bolanos, O., additional, Augostini, R., additional, Pelini, M., additional, Zhang, S., additional, Stoycos, S., additional, Witsaman, S., additional, Mowrey, K., additional, Bremer, J., additional, Oza, A., additional, Ciconte, G., additional, Mazzone, P., additional, Paglino, G., additional, Marzi, A., additional, Vergara, P., additional, Sora, N., additional, Gulletta, S., additional, Della Bella, P., additional, Nagashima, M., additional, Goya, M., additional, Soga, Y., additional, Hiroshima, K., additional, Andou, K., additional, Hayashi, K., additional, An, Y., additional, Nobuyoshi, M., additional, Kutarski, A., additional, Malecka, B., additional, Pietura, R., additional, Osmancik, P., additional, Herman, D., additional, Stros, P., additional, Kocka, V., additional, Tousek, P., additional, Linkova, H., additional, Bortnik, M., additional, Occhetta, E., additional, Dell'era, G., additional, Degiovanni, A., additional, Plebani, L., additional, Marino, P. N., additional, Gorev, M. V., additional, Alimov, D. G., additional, Raju, P., additional, Kully, S., additional, Ugni, S., additional, Furniss, S., additional, Lloyd, G., additional, Patel, N. R., additional, Richards, M. W., additional, Warren, C. E., additional, Anderson, M. H., additional, Hero, M., additional, Rey, J. L., additional, Ouali, S., additional, Azzez, S., additional, Kacem, S., additional, Hammas, S., additional, Ben Salem, H., additional, Neffeti, E., additional, Remedi, F., additional, Boughzela, E., additional, Kronborg, M. B., additional, Mortensen, P. T., additional, Poulsen, S. H., additional, Nielsen, J. C., additional, Simantirakis, E. N., additional, Kontaraki, J. E., additional, Arkolaki, E. G., additional, Chrysostomakis, S. I., additional, Nyktari, E. G., additional, Patrianakos, A. P., additional, Funck, R. C., additional, Harink, C., additional, Mueller, H. H., additional, Koelsch, S., additional, Maisch, B., additional, Bolzani, V., additional, Costandi, P., additional, Shehada, R. E., additional, Butala, N., additional, Coppola, B., additional, Taborsky, M., additional, Heinc, P., additional, Fedorco, M., additional, Doupal, V., additional, Di Cori, A., additional, Zucchelli, G., additional, Soldati, E., additional, Segreti, L., additional, De Lucia, R., additional, Viani, S., additional, Paperini, L., additional, Bongiorni, M. G., additional, Gutleben, K. J., additional, Kranig, W., additional, Barr, C., additional, Morgenstern, M. M., additional, Simon, M., additional, Dalal, Y. H., additional, Landolina, M., additional, Pierantozzi, A., additional, Agricola, T., additional, Lunati, M., additional, Pisano', E., additional, Lonardi, G., additional, Bardelli, G., additional, Zucchi, G., additional, Thibault, B., additional, Dubuc, M., additional, Karst, E., additional, Ryu, K., additional, Paiement, P., additional, Carlson, M. D., additional, Farazi, T., additional, Alhous, H., additional, Mont, L., additional, Porres, J. M., additional, Alzueta, J., additional, Beiras, X., additional, Fernandez-Lozano, I., additional, Macias, A., additional, Ruiz, R., additional, Brugada, J., additional, Viani, S. M., additional, Seifert, M., additional, Schau, T., additional, Moeller, V., additional, Meyhoefer, J., additional, Butter, C., additional, Ganiere, V., additional, Niculescu, V., additional, Domenichini, G., additional, Stettler, C., additional, Defaye, P., additional, Burri, H., additional, Stockburger, M., additional, De Teresa, E., additional, Lamas, G., additional, Desaga, M., additional, Koenig, C., additional, Cobo, E., additional, Navarro, X., additional, Wiegand, U., additional, Blich, M., additional, Carasso, S., additional, Suleiman, M., additional, Marai, I., additional, Gepstein, L., additional, Boulos, M., additional, Sasov, M., additional, Liska, B., additional, Margitfalvi, P., additional, Malacky, T., additional, Svetlosak, M., additional, Goncalvesova, E., additional, Hatala, R., additional, Takaya, Y., additional, Noda, T., additional, Yamada, Y., additional, Okamura, H., additional, Satomi, K., additional, Shimizu, W., additional, Aihara, N., additional, Kamakura, S., additional, Proclemer, A., additional, Boveda, S., additional, Oswald, H., additional, Scipione, P., additional, Da Costa, A., additional, Brzozowski, W., additional, Tomaszewski, A., additional, Wysokinski, A., additional, Arbelo, E., additional, Tamborero, D., additional, Vidal, B., additional, Tolosana, J. M., additional, Sitges, M., additional, Matas, M., additional, Botto, G. L., additional, Dicandia, C. D., additional, Mantica, M., additional, La Rosa, C., additional, D' Onofrio, A., additional, Molon, G., additional, Raciti, G., additional, Verlato, R., additional, Foley, P. W. X., additional, Chalil, S., additional, Ratib, K., additional, Smith, R. E. A., additional, Printzen, F., additional, Auricchio, A., additional, Leyva, F., additional, Abu Sham'a, R., additional, Buber, J., additional, Luria, D., additional, Kuperstein, R., additional, Feinberg, M., additional, Granit, H., additional, Eldar, M., additional, Glikson, M., additional, Vondrak, K., additional, Nof, E., additional, Lipchenca, I., additional, Vatasescu, R.- G., additional, Iorgulescu, C., additional, Caldararu, C., additional, Vasile, A., additional, Bogdan, S., additional, Constantinescu, D., additional, Dorobantu, M., additional, Sakaguchi, H., additional, Miyazaki, A., additional, Yamamoto, T., additional, Fujimoto, K., additional, Ono, S., additional, Ohuchi, H., additional, Martinelli, M., additional, Martins, S., additional, Molina, R., additional, Siqueira, S., additional, Nishioka, S. A. D., additional, Peixoto, G. L., additional, Alkmim-Teixeira, R., additional, Costa, R., additional, Meine, M. M., additional, Tuinenburg, A. E., additional, Doevendans, P. A., additional, Denollet, J., additional, Goscinska-Bis, K., additional, Zupan, I., additional, Van Der, H., additional, Anselme, F., additional, Hartog, H., additional, Block, M., additional, Borri, A., additional, Padeletti, L., additional, Toniolo, M., additional, Zanotto, G., additional, Rossi, A., additional, Raytcheva, E., additional, Tomasi, L., additional, Vassanelli, C., additional, Fernandez Lozano, I., additional, Mitroi, C., additional, Toquero Ramos, J., additional, Castro Urda, V., additional, Monivas Palomero, V., additional, Corona Figueroa, A., additional, Ruiz Bautista, L., additional, Alonso Pulpon, L., additional, Jadidi, A. S., additional, Sacher, F., additional, Shah, A. S., additional, Scherr, D., additional, Derval, N., additional, Hocini, M., additional, Haissaguerre, M., additional, Castrejon Castrejon, S., additional, Largo-Aramburu, C., additional, Sachar, J., additional, Gang, E., additional, Estrada, A., additional, Doiny, D., additional, De Miguel, E., additional, Merino, J. L., additional, Trevisi, N., additional, Ricco, A., additional, Petracca, F., additional, Baratto, F., additional, Bisceglie, A., additional, Maccabelli, G., additional, El-Damaty, A., additional, Sapp, J., additional, Warren, J., additional, Macinnis, P., additional, Horacek, M., additional, Dinov, B., additional, Schoenbauer, R., additional, Braunschweig, F., additional, Arya, A., additional, Andreu, D., additional, Berruezo, A., additional, Ortiz, J. T., additional, Silva, E., additional, De Caralt, T. M., additional, Fernandez-Armenta, J., additional, Perez-Silva, A., additional, Ortega, M., additional, Lopez-Sendon, J. L., additional, Regoli, F., additional, Faletra, F., additional, Nucifora, G., additional, Pasotti, E., additional, Moccetti, T., additional, Klersy, C., additional, Casella, M., additional, Dello Russo, A., additional, Moltrasio, M., additional, Zucchetti, M., additional, Fassini, G., additional, Di Biase, L., additional, Natale, A., additional, Tondo, C., additional, Matsuhashi, N., additional, Weig, H. J., additional, Kerst, G., additional, Weretk, S., additional, Seizer, P., additional, Gawaz, M. P., additional, Schreieck, J., additional, Sarquella-Brugada, G., additional, Prada, F., additional, Salling, C. M., additional, Kolb, C., additional, Pytkowski, M., additional, Maciag, A., additional, Farkowski, M., additional, Jankowska, A., additional, Kowalik, I., additional, Kraska, A., additional, Szwed, H., additional, Maury, P., additional, Duparc, A., additional, Mondoly, P., additional, Rollin, A., additional, Pap, R., additional, Kohari, M., additional, Bencsik, G., additional, Makai, A., additional, Saghy, L., additional, Forster, T., additional, Ebrille, E., additional, Scaglione, M., additional, Raimondo, C., additional, Caponi, D., additional, Di Donna, P., additional, Blandino, A., additional, Delcre, S. D. L., additional, Gaita, F., additional, Roca Luque, I., additional, Dos, L. D. S., additional, Rivas, N. R. G., additional, Pijuan, A. P. D., additional, Perez, J., additional, Casaldaliga, J., additional, Garcia-Dorado, D. G. D., additional, Moya, A. M. M., additional, Sato, H., additional, Yagi, T., additional, Yambe, T., additional, Streitner, F., additional, Dietrich, C., additional, Mahl, E., additional, Schoene, N., additional, Veltmann, C., additional, Borggrefe, M., additional, Kuschyk, J., additional, Sadarmin, P. P., additional, Wong, K. C. K., additional, Rajappan, K., additional, Bashir, Y., additional, Betts, T. R., additional, Leclercq, C., additional, Martins, R., additional, Daubert, J. C., additional, Mabo, P., additional, Koide, M., additional, Hamano, G., additional, Taniguchi, T., additional, Yamato, M., additional, Sasaki, N., additional, Hirooka, K., additional, Ikeda, Y., additional, Yasumura, Y., additional, Dichtl, W., additional, Wolber, T., additional, Paoli, U., additional, Bruellmann, S., additional, Berger, T., additional, Stuehlinger, M., additional, Duru, F., additional, Hintringer, F., additional, Kanoupakis, E., additional, Mavrakis, H., additional, Koutalas, E., additional, Saloustros, I., additional, Goudis, C., additional, Chlouverakis, G., additional, Vardas, P., additional, Herre, J. M., additional, Saeed, M., additional, Saberi, L., additional, Neuman, S., additional, Yamaji, K., additional, Iwabuchi, M., additional, Baranchuk, A., additional, Femenia, F., additional, Miranda Hermosilla, R., additional, Lopez Diez, J. C., additional, Serra, J. L., additional, Valentino, M., additional, Retyk, E., additional, Galizio, N., additional, Kwasniewski, W., additional, Filipecki, A., additional, Orszulak, W., additional, Urbanczyk-Swic, D., additional, Trusz - Gluza, M., additional, Piot, O., additional, Degand, B., additional, Donofrio, A., additional, Scanu, P., additional, Quesada, A., additional, Kloppe, A., additional, Mijic, D., additional, Bogossian, H., additional, Zarse, M., additional, Lemke, B., additional, Tyler, J., additional, Comfort, G., additional, Deering, T. F., additional, Epstein, A. E., additional, Greenberg, S. M. G., additional, Goldman, D. S., additional, Rhude, J., additional, Majewski, J. P., additional, Lelakowski, J., additional, Tomala, I., additional, Santos, C. M., additional, Miranda, R. S., additional, Sousa, P. J., additional, Cavaco, D. M., additional, Adragao, P. P., additional, Knops, R. E., additional, Wilde, A. A., additional, Belhameche, M., additional, Hermida, J. S., additional, Dovellini, E., additional, Frohlig, G., additional, Siot, P., additional, Duray, G. Z., additional, Israel, C. W., additional, Brachmann, J., additional, Seidl, K. H., additional, Foresti, M., additional, Birkenhauer, F., additional, Hohnloser, S. H., additional, Ferreira, C., additional, Mateus, P., additional, Ribeiro, H., additional, Carvalho, S., additional, Ferreira, A., additional, Moreira, J., additional, Kadro, W., additional, Rahim, H., additional, Turkmani, M., additional, Abu Lebdeh, M., additional, Altabban, A., additional, Cerrato, N., additional, Rivera, S., additional, Scazzuso, F., additional, Albina, G., additional, Klein, A., additional, Laino, R., additional, Sammartino, V., additional, Giniger, A., additional, Kvantaliani, T., additional, Akhvlediani, M., additional, Namdar, M., additional, Steffel, J., additional, Jetzer, S., additional, Bayrak, F., additional, Chierchia, G. B., additional, Jenni, R., additional, Brugada, P., additional, Bakos, Z., additional, Medvedev M, M. M., additional, Jonas Carlsson, J. C., additional, Fredrik Holmqvist, F. H., additional, Pyotr Platonov, P. P., additional, Nurbaev, T., additional, Pirnazarov, M., additional, Nikishin, A., additional, Aagaard, P., additional, Sahlen, A., additional, Bergfeldt, L., additional, Simeonidou, E., additional, Kastellanos, S., additional, Varounis, C., additional, Michalakeas, C., additional, Koniari, C., additional, Nikolopoulou, A., additional, Anastasiou-Nana, M., additional, Furukawa, Y., additional, Yamada, T., additional, Morita, T., additional, Tanaka, K., additional, Iwasaki, Y., additional, Kawasaki, M., additional, Kuramoto, Y., additional, Fukunami, M., additional, Blanche, C., additional, Tran, N., additional, Rigamonti, F., additional, Zimmermann, M., additional, Okisheva, E., additional, Tsaregorodtsev, D., additional, Sulimov, V., additional, Novikova, D., additional, Popkova, T., additional, Udachkina, E., additional, Korsakova, Y., additional, Volkov, A., additional, Novikov, A., additional, Alexandrova, E., additional, Nasonov, E., additional, Arsenos, P., additional, Gatzoulis, K., additional, Manis, G., additional, Dilaveris, P., additional, Gialernios, T., additional, Kartsagoulis, E., additional, Asimakopoulos, S., additional, Stefanadis, C., additional, Marocolo, M., additional, Barbosa Neto, O., additional, Carvalho, A. C., additional, Marques Neto, S. R., additional, Mota, G. R., additional, Barbosa, P. R. B., additional, Fernandez-Fernandez, A., additional, Manzano Fernandez, S., additional, Pastor-Perez, F. J., additional, Barquero-Perez, O., additional, Goya-Esteban, R., additional, Salar, M., additional, Rojo-Alvarez, J. L., additional, Garcia-Alberola, A., additional, Takigawa, M., additional, Kawamura, M., additional, Aiba, T., additional, Sakaguchi, T., additional, Itoh, H., additional, Horie, M., additional, Igarashi, T., additional, Negishi, J., additional, Toyota, N., additional, Yamada, O., additional, Papavasileiou, M., additional, Cabrera Bueno, F., additional, Molina Mora, M. J., additional, Alzueta Rodriguez, J., additional, Barrera Cordero, A., additional, De Teresa Galvan, E., additional, Revishvili, A. S., additional, Dzhordzhikiya, T., additional, Sopov, O., additional, Simonyan, G., additional, Lyadzhina, O., additional, Fetisova, E., additional, Kalinin, V., additional, Balt, J. C., additional, Steggerda, R. C., additional, Boersma, L. V. A., additional, Wijffels, M. C. E. F., additional, Wever, E. F. D., additional, Ten Berg, J. M., additional, Ricci, R. P., additional, Morichelli, L., additional, D'onofrio, A., additional, Vaccari, D., additional, Calo', L., additional, Buja, G., additional, Rovai, N., additional, Gargaro, A., additional, Sperzel, J., additional, Speca, G., additional, Santini, L., additional, Haarbo, J., additional, Dubin, K., additional, Carlson, M., additional, Garcia Quintana, A., additional, Mendoza-Lemes, H., additional, Garcia Perez, L., additional, Led Ramos, S., additional, Caballero Dorta, E., additional, Matinez De Espronceda, M., additional, Piro Mastracchio, V., additional, Serrano Arriezu, L., additional, Sciarra, L., additional, Marziali, M., additional, Marras, E., additional, Rebecchi, M., additional, Allocca, G., additional, Lioy, E., additional, Delise, P., additional, Santobuono, V. E., additional, Iacoviello, M., additional, Nacci, F., additional, Luzzi, G., additional, Puzzovivo, A., additional, Memeo, M., additional, Quadrini, F., additional, Favale, S., additional, Trucco, M. E., additional, Arce, M., additional, Palazzolo, J., additional, Uribe, W., additional, Maggi, R., additional, Furukawa, T., additional, Croci, F., additional, Solano, A., additional, Brignole, M., additional, Lebreiro, A., additional, Sousa, A., additional, Correia, A. S., additional, Lourenco, P., additional, Oliveira, S., additional, Paiva, M., additional, Freitas, J., additional, Maciel, M. J., additional, Linker, N., additional, Rieger, G., additional, Garutti, C., additional, Edvardsson, N., additional, Salguero Bodes, R., additional, De Riva Silva, M., additional, Fontenla Cerezuela, A., additional, Lopez Gil, M., additional, Mejia Martinez, E., additional, Jurado Roman, A., additional, Garcia Alvarez, S., additional, Arribas Ynsaurriaga, F., additional, Petix, N. R., additional, Del Rosso, A., additional, Guarnaccia, V., additional, Zipoli, A., additional, Rabajoli, F., additional, Foglia Manzillo, G., additional, Tolardo, C., additional, Checchinato, C., additional, Chiaravallotti, S., additional, Santarone, M., additional, Spinnler, M. T., additional, Podoleanu, C., additional, Frigy, A., additional, Dobreanu, D., additional, Ginghina, C., additional, and Carasca, E., additional
- Published
- 2011
- Full Text
- View/download PDF
16. Quality of life improvement after radiofrequency catheter ablation of outflow tract ventricular arrhythmias in patients with structurally normal hearts
- Author
-
Pytkowski, M., Maciag, A., Jankowska, A., Kowalik, I., Krask, A., Farkowski, M., Golicki, D., and Szwed, H.
- Published
- 2012
- Full Text
- View/download PDF
17. Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation -- a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study)
- Author
-
Farkowski Michal M, Maciag Aleksander, Dabrowski Rafal, Pytkowski Mariusz, Kowalik Ilona, and Szwed Hanna
- Subjects
Antazoline ,Atrial fibrillation ,Pharmacological cardioversion ,Efficacy ,Safety ,Randomized clinical trial ,Medicine (General) ,R5-920 - Abstract
Abstract Background Rapid conversion of atrial fibrillation (AF) to sinus rhythm may be achieved by the administration of class IA, IC and III antiarrhythmic drugs or vernakalant hydrochloride. However, that treatment may be related to potential pro-arrhythmia, lack of efficacy or the exceptionally high cost of a compound used. Antazoline is a first generation antihistaminic agent with chinidin-like properties. When administered intravenously, antazoline exerts a strong antiarrhythmic effect on supraventricular arrhythmia, especially on AF, facilitating rapid conversion to sinus rhythm. Despite a relative lack of published data antazoline has been marketed in Poland and widely used in cardiology wards and emergency rooms for many years due to its efficacy, safety and rapid onset of action within minutes of administration. Methods/design A randomized, double blind, placebo-controlled, superiority clinical trial was designed to assess clinical efficacy of antazoline in rapid conversion of AF to sinus rhythm. Eligible patients will present AF lasting less than 43 hours, will be in stable cardio-pulmonary condition and will have no prior history of advanced heart failure or significant valvular disease. Long-term antiarrhythmic therapy is not considered an exclusion criterion. Subjects who fulfill selection criteria will be randomly assigned to receive intravenously either antazoline or placebo in divided doses and observed for 1.5 hours after conversion to sinus rhythm or after the last i.v. bolus. Primary end point will be the conversion of AF to sinus rhythm confirmed in an electrocardiogram (ECG) during the observation period. Secondary end points will be comprised of time to conversion and return of AF during the observation period. Special consideration will be given to the observation of any adverse events. A sample size of 80 patients was calculated based on the following assumptions: two-tailed test, a type I error of 0.01, a power of 90%, efficacy of placebo 5%, efficacy of antazoline 50% and 20% drop-out rate to fulfill the criteria of intention-to-treat analysis. Due to the presumed lack of statistical power, the secondary end points and safety endpoints will be considered exploratory. Clinical trials registry ClinicalTrials.gov, NCT01527279
- Published
- 2012
- Full Text
- View/download PDF
18. Position of experts of the Polish Cardiac Society in the field of cardiomyopathy.
- Author
-
Mizia-Stec K, Burchardt P, Mazurkiewicz Ł, Tajstra M, Wybraniec M, Mitkowski P, Bartuś S, Biernacka EK, Gierlotka M, Sterliński M, Wojakowski W, Witkowski A, Gil RJ, Farkowski M, Szymański P, Tycińska A, Kowalski O, Grzybowski J, and Leszek P
- Published
- 2024
- Full Text
- View/download PDF
19. Catheter ablation for atrial fibrillation and impact on clinical outcomes.
- Author
-
Providencia R, Ali H, Creta A, Barra S, Kanagaratnam P, Schilling RJ, Farkowski M, and Cappato R
- Abstract
Aims: Catheter ablation is the most effective rhythm-control option in patients with atrial fibrillation (AF) and is currently considered an option mainly for improving symptoms. We aimed to assess the impact of catheter ablation on hard clinical outcomes., Methods and Results: We performed a systematic review of randomized controlled trials (RCTs) comparing catheter ablation vs. optimized medical treatment. We searched MEDLINE, EMBASE, and CENTRAL on 8 January 2024, for trials published ≤10 years. We pooled data through risk ratio (RR) and mean differences (MDs), with 95% confidence interval (CI), and calculated the number needed to treat (NNT). Sub-group and sensitivity analyses were performed for the presence/absence of heart failure (HF), paroxysmal/persistent AF, early ablation, higher/lower quality, and published ≤5 vs. >5 years. Twenty-two RCTs were identified, including 6400 patients followed for 6-52 months. All primary endpoints were significantly reduced by catheter ablation vs. medical management: all-cause hospitalization (RR = 0.57, 95% CI 0.39-0.85, P = 0.006), AF relapse (RR = 0.48, 95% CI 0.39-0.58, P < 0.00001), and all-cause mortality (RR = 0.69, 95% CI 0.56-0.86, P = 0.0007, NNT = 44.7, driven by trials with HF patients). A benefit was also demonstrated for all secondary endpoints: cardiovascular mortality (RR = 0.55, 95% CI 0.34-0.87), cardiovascular (RR = 0.83, 95% CI 0.71-0.96), and HF hospitalizations (RR = 0.71, 95% CI 0.56-0.89), AF burden (MD = 20.6%, 95% CI 5.6-35.5), left ventricular ejection fraction (LVEF) recovery (MD = 5.7%, 95% CI 3.5-7.9), and quality of life (MLHFQ, AFEQT, and SF-36 scales)., Conclusion: Catheter ablation significantly reduced hospitalizations, AF burden, and relapse, and improved quality of life. An impact on hard clinical outcomes, with an important mortality reduction and improvement in LVEF, was seen for patients with AF and HF., Competing Interests: Conflict of interest: Professor Rui Providencia has a Research Grant from Biosense-Webster for supporting a PhD Fellow on a project on AF mechanisms and genetics; Professor Riccardo Cappato reports grants from Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Johnson and Johnson, grants and personal fees from Boston Scientific, Medtronic, Abbott and Biosense-Webster; No other conflicts of interest to report., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
20. Concise guidelines of the European Cardiac Arrhythmias Society (ECAS) on "catheter ablation of atrial fibrillation": A prepublication of the methods in preparation of the final guidelines document.
- Author
-
Cappato R, Levy S, Providencia R, Ali H, Ardashev A, Barra S, Creta A, Farkowski M, Heeger CH, Kanagaratnam P, Lewalter T, Magnani S, Shah D, and Schilling R
- Subjects
- Humans, Treatment Outcome, Consensus, Europe, Cardiology standards, Evidence-Based Medicine standards, Atrial Fibrillation surgery, Atrial Fibrillation diagnosis, Atrial Fibrillation physiopathology, Catheter Ablation standards
- Published
- 2024
- Full Text
- View/download PDF
21. Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference.
- Author
-
Linz D, Andrade JG, Arbelo E, Boriani G, Breithardt G, Camm AJ, Caso V, Nielsen JC, De Melis M, De Potter T, Dichtl W, Diederichsen SZ, Dobrev D, Doll N, Duncker D, Dworatzek E, Eckardt L, Eisert C, Fabritz L, Farkowski M, Filgueiras-Rama D, Goette A, Guasch E, Hack G, Hatem S, Haeusler KG, Healey JS, Heidbuechel H, Hijazi Z, Hofmeister LH, Hove-Madsen L, Huebner T, Kääb S, Kotecha D, Malaczynska-Rajpold K, Merino JL, Metzner A, Mont L, Ng GA, Oeff M, Parwani AS, Puererfellner H, Ravens U, Rienstra M, Sanders P, Scherr D, Schnabel R, Schotten U, Sohns C, Steinbeck G, Steven D, Toennis T, Tzeis S, van Gelder IC, van Leerdam RH, Vernooy K, Wadhwa M, Wakili R, Willems S, Witt H, Zeemering S, and Kirchhof P
- Subjects
- Humans, Risk, Hemorrhage, Anticoagulants therapeutic use, Atrial Fibrillation complications, Atrial Fibrillation diagnosis, Atrial Fibrillation epidemiology, Stroke etiology, Stroke prevention & control
- Abstract
Aims: Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated with a low risk of AF-related complications. The aim of this document is to summarize the key outcomes of the 9th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA)., Methods and Results: Eighty-three international experts met in Münster for 2 days in September 2023. Key findings are as follows: (i) Active rhythm management should be part of the default initial treatment for all suitable patients with AF. (ii) Patients with device-detected AF have a low burden of AF and a low risk of stroke. Anticoagulation prevents some strokes and also increases major but non-lethal bleeding. (iii) More research is needed to improve stroke risk prediction in patients with AF, especially in those with a low AF burden. Biomolecules, genetics, and imaging can support this. (iv) The presence of AF should trigger systematic workup and comprehensive treatment of concomitant cardiovascular conditions. (v) Machine learning algorithms have been used to improve detection or likely development of AF. Cooperation between clinicians and data scientists is needed to leverage the potential of data science applications for patients with AF., Conclusions: Patients with AF and a low arrhythmia burden have a lower risk of stroke and other cardiovascular events than those with a high arrhythmia burden. Combining active rhythm control, anticoagulation, rate control, and therapy of concomitant cardiovascular conditions can improve the lives of patients with AF., Competing Interests: Conflict of interest The 9th AFNET/EHRA consensus conference was partially supported by the European Union MAESTRIA project (grant agreement 965286) to AFNET. The following participants and authors are employees of companies active in cardiovascular health as indicated in their affiliations: M.D.M., E.D., C.E., G.H., L.H.H., T.H., R.H.v.L., M.W., and H.W. P.K. was partially supported by the European Union AFFECT-AF (grant agreement 847770) and MAESTRIA (grant agreement 965286), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), and Leducq Foundation. He receives research support for basic, translational, and clinical research projects from several drug and device companies active in AF and has received honoraria from several such companies in the past, but not in the last 3 years. He is listed as an inventor on two issued patents held by the University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). J.G.A. was partially supported by the Canadian Arrhythmia Network and the Michael Smith Foundation for Health Research, Baylis Medical. He receives consulting fees/honoraria from Bayer, BMS/Pfizer Alliance, Servier, and Medtronic Inc. E.A. receives consulting fees/honoraria from Biosense Webster and Bayer. G.B. receives consulting fees/honoraria from Bayer, BMS, Boston Scientific, Daiichi Sankyo, Sanofi, and Janssen. A.J.C. receives consulting fees/honoraria from Bayer, Pfizer/BMS, Daiichi Sankyo, Menarini, Sanofi, Boston Scientific, Biosense Webster, Abbott, Acesion Pharma, Huya Bio, and Milestone. V.C. receives consulting fees/honoraria from Bayer, Boehringer Ingelheim, and Ever Pharma (paid to the institution of employment). W.D. receives consulting fees/honoraria from Reata and research grants from MicroPort, Boston Scientific, and Abbott. S.Z.D. receives consulting fees from BMS/Pfizer, Cortrium, and Acesion Pharma and speaker fees from MS/Pfizer and Bayer. He is listed as a medical advisor for Vital Beats. Dobromir D. receives consulting fees/honoraria from Elsevier, Springer Healthcare Ltd, and Daiichi Sankyo and research grants as follows: four NIH grants (partially) from Baylor College of Medicine, Houston; one NIH grant from UC Davis, one NIH grant from the University of Minnesota, and one EU-Project H2020. David D. receives consulting fees/honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientific, BMS/Pfizer, CVRx, Medtronic, MicroPort, and Zoll and research grants from Roche, CVRx, and Zoll. L.E. has received lecture fees from various companies in AF in the past but none related to the present work. L.F. receives consulting fees/honoraria from Roche (paid to the institution of employment). She is currently employed at the UKE and previously at the University of Birmingham. She was partially supported by the European Union AFFECT-EU (grant agreement 847770), MAESTRIA (grant agreement 965286), CATCH ME (grant agreement 633196), and the British Heart Foundation (AA/18/2/3218). D.F.-R. receives research grants from Abbott. He is listed as an inventor on two issued patents: EP3636147A1 (method for the identification of cardiac fibrillation drivers and/or the footprint of rotational activations) and PCT/EP2022/071364 (system and method of assessment of electromechanical remodelling). A.G. receives consulting fees/honoraria from Daiichi Sankyo, Bayer, BMS/Pfizer, Medtronic, Abbott, and Boston Scientific and was partially supported by the European Union MAESTRIA (grant agreement 965286). K.G.H. receives consulting fees/honoraria from Abbott, Alexion, Amarin, Astra Zeneca, Bayer Healthcare, Biotronik, Boehringer Ingelheim, Boston Scientific, BMS/Pfizer, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Novaris, Portola, Premier Research, Sanofi, SUN Pharma, and W. L. Gore and Associates. J.S.H. receives speaking fees from BMS/Pfizer, Bayer, Servier, and Boston Scientific and consulting fees from Bayer and Boston Scientific. He receives research grants from BMS/Pfizer, Servier, Novartis, Boston Scientific, and Medtronic. H.H. receives lecture and consulting fees from Bayer, Biotronik, BMS/Pfizer, Daiichi Sankyo, Milestone Pharmaceuticals, Centrix India, C.T.I. Germany, ESC, Medscape, and Springer Healthcare Ltd. He receives research grants (paid to the institution of employment, University of Antwerp and/or University of Hasselt) from Abbott, Bayer, Biosense Webster, Boston Scientific, Daiichi Sankyo, Fibricheck/Qompium, Medtronic, and BMS/Pfizer. Z.H. receives consulting fees/honoraria from Boehringer Ingelheim, BMS/Pfizer, and Roche Diagnostics. He was partially supported by The Swedish Society for Medical Research (S17-0133), Hjärt-Lungfonden (The Swedish Heart-Lung Foundation, 20200722), and the institution he is currently employed at (Uppsala University Hospital). L.H.-M. receives research grants from the Spanish Ministry of Science and Innovation (PID2020-116927RB-C21) and Fondo Europeo de Desarrollo Regional (FEDER). D.K. receives consulting fees/honoraria from Bayer, Amomed, and Protherics Medicines Development. He receives research grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RAE-AF; NIHR130280 DaRe2THINK; NIHR13274 D2T-NeuroVascular; and NIHR203326 Biomedical Research Centre), the British Heart Foundation (PG/17/55/33087, AA/182/3218, and FS/CDRF/21/21032), the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074), EU Horizon and UKRI (HYPERMARKER 101095480) UK National Health Service—Data for R&D-Subnational Secure Data Environment programme, UK Department for Business, Energy Industrial Strategy Regulators Pioneer Fund, the Cook & Wolstenholme Charitable Trust, and the European Society of Cardiology supported by educational grants from Boehringer Ingelheim, BMS/Pfizer, Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR/University of Oxford Biomedical Research Centre, and the British Hear Foundation, the University of Birmingham Accelerator Award (STEEER-AF). J.L.M. receives consulting fees/honoraria from Biotronik, Medtronic, MicroPort, and Milestone Pharmaceuticals. A.M. receives consulting fees/honoraria from Medtronic, Biosense Webster, and Boston Scientific and lecture fees from Medtronic, Boston Scientific, Biosense Webster, BMS, and Bayer. L.M. receives consulting fees/honoraria from Abbott, Medtronic, Boston Scientific, and Johnson & Johnson. G.A.N. receives lecture fees from AliveCor, consultant fees from Biosense Webster, and research grants from Abbott and Biosense Webster. H.P. receives consulting fees/honoraria from Abbott, Boston Scientific, Biosense Webster, Medtronic, Daiichi Sankyo, Bayer, and Pfizer. P.S. receives consulting fees/honoraria from Medtronic, Boston Scientific, Abbott, CathRx, and PaceMate (paid to the institution of employment). He is currently employed at the University of Adelaide, which receives research grants from Medtronic, Boston Scientific, and Becton-Dickenson. R.B.S. receives consulting fees/honoraria from BMS/Pfizer. She was partially supported by the European Union Horizon 2020 research and innovation programme (grant agreement 648131 and 847770), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers 81Z1710103 and 81Z0710114), German Ministry of Research and Education (BMBF 01ZX1408A), ERACoSysMed3 (031L0239), Wolfgang Seefried project funding German Heart Foundation. U.S. receives consulting fees/honoraria from University Svizzerra Italiana, Stanford, and Johnson & Johnson and research grants from the European Union, Dutch Heart Foundation, Roche, and EP Solution. He is a shareholder of YourRhythmics B.V. T.T. receives consulting fees/honoraria from Boston Scientific and Medtronic. I.C.v.G. receives consulting fees/honoraria from Bayer (paid to the institution of employment). She is currently employed at the University of Groningen. K.V. receives consulting fees/honoraria from Abbott, Philips, Medtronic, Biosense Webster, and Boston Scientific and research grants from Medtronic and Biosense Webster. R.W. receives consulting fees/honoraria from Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Boston Scientific, Biotronik, Abiomed, and Zoll and a research grant from Boston Scientific, BMS/Pfizer, and Abiomed. S.W. receives consulting fees/honoraria from Boehringer Ingelheim, Boston Scientific, Abbott, and Bayer Vital and a research grant from Boston Scientific. All remaining authors (G.B., J.C.N., T.D.P., N.D., M.F., E.G., S.H., S.K., D.L., K.M.-R., M.O., A.S.P., U.R., M.R., D.S., C.S., G.S., D.S., S.T., R.H.v.L., and S.Z.) have declared no conflicts of interest., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
22. Prevention of venous thromboembolism in right heart-sided electrophysiological procedures: results of an European Heart Rhythm Association survey.
- Author
-
Mugnai G, Farkowski M, Tomasi L, Roten L, Migliore F, de Asmundis C, Conte G, Boveda S, and Chun JKR
- Subjects
- Humans, Anticoagulants therapeutic use, Fibrinolytic Agents therapeutic use, Heparin, Aspirin, Surveys and Questionnaires, Venous Thromboembolism epidemiology, Venous Thromboembolism prevention & control, Pulmonary Embolism prevention & control, Pulmonary Embolism drug therapy
- Abstract
Limited data are available regarding venous thromboembolism (VTE), specifically deep vein thrombosis (DVT) and pulmonary embolism (PE), following right-sided ablations and electrophysiological (EP) studies. Compared to left-sided procedures, no guidelines on antithrombotic management strategies for the prevention of DVT and PE are available. The main purpose of the present European Heart Rhythm Association (EHRA) survey is to report the current management of right-sided EP procedures, focusing on anticoagulation and prevention of VTE. An online survey was conducted using the EHRA infrastructure. A total of 244 participants answered a 19-items questionnaire on the periprocedural management of EP studies and right-sided catheter ablations. The right femoral vein is the most common access for EP studies and right-sided procedures. An ultrasound-guided approach is employed by more than 2/3 of respondents. Intravenous heparin is not commonly given by the majority of participants. About 1/3 of participants (34%) routinely prescribe VTE prophylaxis during (mostly aspirin and low molecular weight heparin) and 1/4 of respondents (25%) commonly prescribe VTE prophylaxis after discharge (mostly aspirin). Of note, respectively 13% and 9% of participants observed at least one DVT and one PE related to right-sided ablation or EP study within the last year in their center. The present survey shows that only a minority of operators routinely gives intraprocedural intravenous heparin and prescribes VTE prophylaxis after right-sided EP procedures. Compared to left-sided procedures like atrial fibrillation (AF) ablation, there are no consistent systematic antithrombotic management strategies., Competing Interests: Conflict of interest: M.F. received speaker and consultation fees from Pfizer and Boehringer Ingelheim Poland. L.R. has received speaker and consulting fees from Abbott and Medtronic and a research grant to the institution from Medtronic. C.d.A. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Livanova, Boston Scientific, Atricure, Acutus Medical, and Daiichi Sankyo. G.C. has received honoraria fees from Biosense Webster and Boston Scientific and research grants from Boston Scientific. S.B. is a consultant for Medtronic, Boston Scientific, Microport, and Zoll. J.K.R.C. received speaker, consultation, teaching, and proctoring honoraria from Medtronic, Boston Scientific, and Biosense Webster., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
23. Diagnostic and therapeutic pathways for the malignant left atrial appendage: European Heart Rhythm Association physician survey.
- Author
-
Anic A, Bakovic D, Jurisic Z, Farkowski M, Lisica L, Breskovic T, Nielsen-Kudsk JE, Perrotta L, de Asmundis C, Boveda S, and Chun J
- Subjects
- Humans, Anticoagulants therapeutic use, Echocardiography, Transesophageal, Fibrinolytic Agents therapeutic use, Surveys and Questionnaires, Treatment Outcome, Atrial Appendage diagnostic imaging, Atrial Fibrillation complications, Atrial Fibrillation diagnosis, Atrial Fibrillation drug therapy, Stroke prevention & control, Stroke complications, Heart Diseases, Thrombosis epidemiology, Embolism
- Abstract
Aims: Patients with atrial fibrillation who despite taking oral anti-coagulant therapy (OAT) suffer a stroke or systemic embolism (SSE) without vascular cause or who develop left atrial appendage (LAA) thrombus (LAAT) should be considered as having malignant LAA. The optimal treatment strategy to reduce SSE risk in such patients is unknown. The aim of the study is to investigate the diagnostic and therapeutic pathways for malignant LAA practiced in European cardiac centres., Methods and Results: An 18-item online questionnaire on malignant LAA was disseminated by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee. A total of 196 physicians participated in the survey. There seems to be high confidence in transoesophageal echocardiography (TEE) imaging, considering LAAT diagnosis. Switching to another direct oral anti-coagulant (DOAC) is the preferred initial step for the treatment of malignant LAA followed by a switch to vitamin K antagonist (VKA), low-molecular-weight heparin, or continued/optimized DOAC dosage, whereas LAA closure is the last option. Left atrial appendage closure is a viable option in patients with embolic stroke despite OAT and no evidence of thrombus at TEE (empty LAA) after comprehensive diagnostic measures to exclude other sources of embolism., Conclusion: This EHRA survey provides a snapshot of the contemporary management of patients diagnosed with malignant LAA. Currently, the majority of patients are treated on an outpatient basis with either shifting from VKA to DOAC or from one DOAC to another. Left atrial appendage closure in this population seems to be reserved for patients with higher bleeding risk or complications of malignant LAA, such as stroke., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
24. Antiarrhythmic drugs for pharmacological cardioversion of atrial fibrillation and sex differences: Insights from the CANT II Study.
- Author
-
Wybraniec MT, Maciąg A, Miśkowiec D, Ceynowa-Sielawko B, Balsam P, Wójcik M, Wróbel W, Farkowski M, Ćwiek-Rębowska E, Szołkiewicz M, Ozierański K, Błaszczyk R, Bula K, Dembowski T, Peller M, Krzowski B, Wyganowska-Kapryan A, Wańha W, Koziński M, Kasprzak JD, Szwed H, and Mizia-Stec K
- Subjects
- Female, Humans, Male, Amiodarone, Antazoline adverse effects, Antazoline pharmacology, Electric Countershock, Propafenone adverse effects, Propafenone pharmacology, Treatment Outcome, Sex Factors, Multicenter Studies as Topic, Anti-Arrhythmia Agents adverse effects, Anti-Arrhythmia Agents pharmacology, Atrial Fibrillation drug therapy
- Abstract
Background: Data on sex differences in terms of action of antiarrhythmic agents (AADs) are limited. This study aimed to evaluate the clinical profile of patients with atrial fibrillation (AF), and efficacy and safety of AADs used for pharmacological cardioversion (PCV) of AF., Methods: This research was a sub-analysis of the retrospective multicenter Cardioversion with ANTazoline II (CANT) registry, which comprised 1365 patients with short-duration AF referred for urgent PCV with the use of AAD. Patients were categorized according to and compared in terms of clinical parameters and PCV outcomes. The primary endpoint was return of sinus rhythm within 12 hours after drug infusion, and the composite safety endpoint involved bradycardia <45 bpm, hypotension, syncope, or death., Results: The sex distribution of patients qualified for PCV was even (men, n = 725; 53.1%). Females were older and more symptomatic and had higher CHA2DS2-VASc scores, higher prevalence of tachyarrhythmia, and higher use of chronic anticoagulation. The overall efficacy (71.4% vs. 70.1%; P = 0.59) and safety (5.2% vs. 4.6%; P = 0.60) of PCV was comparable in men and women. Amiodarone (68.3% vs. 65.9%; P = 0.66) and antazoline (77.1% vs. 80.0%; P = 0.19) had similar efficacy in men and women, but propafenone had a lower rate of rhythm conversion in men (64.7% vs. 79.3%; P = 0.046). None of the assessed AADs differed in terms of safety profile in both sexes., Conclusion: Female patients with AF have different clinical profiles but similar efficacy and safety of AADs as compared to male participants. Propafenone has significantly lower efficacy in men, which requires further investigation.
- Published
- 2023
- Full Text
- View/download PDF
25. Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study).
- Author
-
Wybraniec MT, Maciąg A, Miśkowiec D, Ceynowa-Sielawko B, Balsam P, Wójcik M, Wróbel W, Farkowski M, Ćwiek-Rębowska E, Szołkiewicz M, Ozierański K, Błaszczyk R, Bula K, Dembowski T, Peller M, Krzowski B, Wańha W, Koziński M, Kasprzak JD, Szwed H, and Mizia-Stec K
- Subjects
- Aged, Anti-Arrhythmia Agents adverse effects, Electric Countershock, Female, Humans, Male, Propafenone therapeutic use, Propensity Score, Registries, Retrospective Studies, Treatment Outcome, Amiodarone adverse effects, Antazoline adverse effects, Antazoline therapeutic use, Atrial Fibrillation
- Abstract
Introduction: Due to safety concerns about available antiarrhythmic drugs (AADs), reliable agents for termination of atrial fibrillation (AF) are requisite., Objectives: The aim of the study was to evaluate the efficacy and safety of antazoline, a first‑generation antihistamine, for cardioversion of recent‑onset AF in the setting of an emergency department., Patients and Methods: This multicenter, retrospective registry covered 1365 patients (median [interquartile range] age, 69.0 [61.0-76.0] years, 53.1% men) with new‑onset AF submitted to urgent pharmacological cardioversion. AAD allocation was performed by the attending physician: antazoline alone was utilized in 600 patients (44%), amiodarone in 287 (21%), propafenone in 150 (11%), and ≥2 AADs in 328 patients (24%). Antazoline in monotherapy or combination was administered to 897 patients (65.7%). Matched antazoline and nonantazoline groups were identified using propensity score matching (PSM, n = 330). The primary end point was return to sinus rhythm within 12 hours after initiation of the treatment., Results: Before PSM, antazoline alone was superior to amiodarone (78.3% vs 66.9%; relative risk [RR], 1.17; 95% CI, 1.07-1.28; P <0.001) and comparable to propafenone (78.3% vs 72.7%; RR, 1.08; 95% CI, 0.97-1.20; P = 0.14) in terms of rhythm conversion rate. In the post‑PSM population, the rhythm conversion rate was higher among patients receiving antazoline alone than in the nonantazoline group (84.2% vs 66.7%; RR, 1.26; 95% CI, 1.11-1.43; P <0.001), and the risk of adverse events was comparable (P = 0.2)., Conclusions: Antazoline appears to be an efficacious agent for termination of AF in real‑world setting. Randomized controlled trials are required to evaluate its safety in specific patient populations.
- Published
- 2022
- Full Text
- View/download PDF
26. The cost of CIED infectious complications treatment in Poland from the perspective of Polish hospitals.
- Author
-
Romanek J, Farkowski M, Bukowski H, Gołba K, Wita K, Mitkowski P, and Przybylski A
- Subjects
- Device Removal adverse effects, Electronics, Hospitals, Humans, Poland, Retrospective Studies, Defibrillators, Implantable adverse effects, Heart Diseases therapy, Pacemaker, Artificial adverse effects, Prosthesis-Related Infections etiology, Prosthesis-Related Infections therapy
- Abstract
Introduction: Cardiac implantable electronic devices (CIED) are a recognized form of therapy in cardiology. Apart from the benefits, the use of CIEDs is also associated with the risk of complications, and the most important ones influencing treatment results and prognosis are infectious complications., Aim: This study aimed to calculate the cost of treatment of CIED-related infections, including transvenous lead extraction and device reimplantation, from the perspective of a Polish hospital., Methods: A retrospective analysis of hospitalization costs of patients referred to transvenous lead extraction (TLE) for CIED infection was performed. The study covers cases from three Polish reference centers specializing in the comprehensive treatment of cardiac electrotherapy complications., Results: It was shown that the average cost of treating a CIED infection is 34 000 PLN (8010 EUR) and is the highest in the cardiac resynchronization therapy with defibrillator function (CRT-D) group, where it amounts to almost 50 000 PLN (11 440 EUR). Thus, treatment of CIED infections is associated with an average loss of 3000 PLN for the healthcare provider and the length of hospitalization has a major influence on final outcomes., Conclusions: The hospital cost of treatment of CIED-related infections was high and related mainly to the type of device and length of hospitalization. Despite the low utilization of costly extraction tools, the hospitalization was still likely to be unprofitable.
- Published
- 2022
- Full Text
- View/download PDF
27. Identification of the ventricular tachycardia circuit using the Advisor HD Grid multielectrode mapping catheter.
- Author
-
Maciąg A, Farkowski M, and Pytkowski M
- Subjects
- Arrhythmias, Cardiac, Catheters, Humans, Catheter Ablation, Tachycardia, Ventricular diagnosis, Tachycardia, Ventricular surgery
- Published
- 2020
- Full Text
- View/download PDF
28. Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial).
- Author
-
Dąbrowski R, Syska P, Mączyńska J, Farkowski M, Sawicki S, Kubaszek-Kornatowska A, Michałek P, Kowalik I, Szwed H, and Hryniewiecki T
- Subjects
- Administration, Intravenous, Adult, Aged, Anti-Arrhythmia Agents adverse effects, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation etiology, Atrial Fibrillation physiopathology, Canrenoic Acid administration & dosage, Case-Control Studies, Double-Blind Method, Electric Countershock adverse effects, Electrocardiography methods, Heart Failure drug therapy, Humans, Middle Aged, Mineralocorticoid Receptor Antagonists administration & dosage, Placebos administration & dosage, Potassium blood, Renin-Angiotensin System drug effects, Safety, Sinoatrial Node physiology, Treatment Outcome, Atrial Fibrillation drug therapy, Canrenoic Acid therapeutic use, Mineralocorticoid Receptor Antagonists therapeutic use, Sinoatrial Node drug effects
- Abstract
Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal disturbances, atrial volume overload). There is still the need for an effective and safe approach to increase AF cardioversion efficacy. This randomized, double-blind, placebo-controlled, superiority clinical study is performed in patients with AF in order to evaluate the clinical efficacy of intravenous canrenone in sinus rhythm restoration., Methods: Eighty eligible patients with an episode of AF lasting less than 48 h are randomized in a 1:1 ratio to receive canrenone or placebo. Patients randomized to a treatment intervention are receiving canrenone intravenously at a dose of 200 mg within 2-3 min. Subjects assigned to a control group obtain the same volume of 0.9% saline within the same time. The primary endpoint includes return of sinus rhythm documented in the electrocardiogram within 2 h after drug or placebo administration. Other endpoints and safety outcomes analyses, due to expected lack of statistical power, are exploratory., Discussion: Current evidence supports renin-angiotensin-aldosterone system (RAAS) inhibition as an upstream therapy in AF management. Excess aldosterone secretion results in proarrhythmic effects. Among the RAAS inhibitors, only canrenone is administered intravenously. Canrenone additionally increases the plasma level of potassium, lowers blood pressure and reduces preload. It has been already used in primary and secondary hyperaldosteronism in the course of chronic liver dysfunction and in heart failure., Trial Registration: ClinicalTrials.gov, NCT03536806. Registered on 25 May 2018.
- Published
- 2020
- Full Text
- View/download PDF
29. "Buddy wire" for facilitation of femoral venous access for cryoablation: a preliminary report.
- Author
-
Maciąg A, Farkowski M, Ciszewski J, Pytkowski M, and Szwed H
- Subjects
- Adult, Aged, Case-Control Studies, Female, Humans, Male, Middle Aged, Pilot Projects, Punctures, Retrospective Studies, Cryosurgery methods, Femoral Vein, Fluoroscopy, Pulmonary Veins surgery
- Abstract
Background: Some electrophysiological techniques, such as balloon cryoablation, involve the use of steerable sheaths of large diameter (outer diameter 15 Fr or more). Their introduction to the femoral vein may be difficult, especially in patients who have had numerous venipunctures in this area., Aim: The authors describe a modification of typical venous access with the use of a "buddy wire" technique, facilitating the insertion of the cryoablation sheaths to the femoral vein., Methods: A case-control study. The study involved a retrospective analysis of 27 consecutive procedures of balloon cryoablation of pulmonary veins performed in 2015 by the first author, compared to 23 consecutive procedures of balloon cryoablation performed in 2014 without a "buddy wire" technique. The study and control groups did not vary significantly. There were 11 women in both groups. The average age of the patients was 55.9 years. The "buddy wire" technique was the only difference in procedure performance between the control and study groups. In the study group a short introducer was inserted through a puncture of the right femoral vein, and then two wires were introduced through it. One of them was secured, so that it could not move, while the other served as a typical trans-septal puncture monitored with the use of X-ray. The standard trans-septal sheet was replaced with a 15 Fr steerable sheath, inserted through the same puncture site next to the secured "buddy wire". The short wire was then removed from the femoral vein. Typical balloon cryoablation of pulmonary veins was performed. After the end of the procedure, the puncture site was secured with a haemostatic suture for 12-18 h., Results: Femoral access with a 15 Fr steerable sheath and cryoablation were safely performed in all patients in the study group and in 22 out of 23 in the control group (100% vs. 95.6%, p = NS). Pulmonary vein isolation in one patient was performed using another technique. No damage to steerable sheaths was observed. There were no vascular complications requiring extended hospitalisation, blood transfusion, or surgical interventions in either group. The "door-to-door" time of the procedures ranged from 2 h 32 min on average in the study group to 2 h 43 min on average in the control group (p = NS). There was significant reduction in fluoroscopy time: 7 min 15 s on average from 11 min 25 s (p = 0.0009)., Conclusions: The use of the "buddy wire" technique may lead to significant reduction in fluoroscopy time during cryoablation of pulmonary veins by facilitating the insertion of the steerable sheaths to the femoral vein.
- Published
- 2017
- Full Text
- View/download PDF
30. Annual Cost Of Conservative Treatment Of Supraventricular Tachycardias In Poland.
- Author
-
Farkowski MM, Golicki D, Czech M, Pytkowski M, Maciag A, Wood KA, Kowalik I, and Szwed H
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.